Credit Suisse Ag Durect Corp Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$0.38 - $0.64 $27 - $46	72 New	72 $0
Q4 2021 Feb 14, 2022	SELL	$0.9 - $1.31 $207,630 - $302,217	-230,700 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$1.21 - $1.61 $11,136 - $14,818	9,204 Added 4.16%	230,700 $296,000
Q2 2021 Aug 16, 2021	BUY	$1.6 - $2.02 $66,025 - $83,357	41,266 Added 22.9%	221,496 $361,000
Q1 2021 May 14, 2021	SELL	$1.86 - $2.87 $118,710 - $183,172	-63,823 Reduced 26.15%	180,230 $357,000
Q4 2020 Feb 12, 2021	BUY	$1.65 - $2.43 $239,984 - $353,431	145,445 Added 147.5%	244,053 $505,000
Q3 2020 Nov 13, 2020	SELL	$1.6 - $2.35 $32,150 - $47,220	-20,094 Reduced 16.93%	98,608 $169,000
Q2 2020 Aug 12, 2020	BUY	$1.33 - $2.76 $157,873 - $327,617	118,702 New	118,702 $275,000
Q3 2019 Nov 12, 2019	SELL	$0.61 - $2.21 $20,532 - $74,388	-33,660 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$0.51 - $0.86 $1,990 - $3,356	-3,903 Reduced 10.39%	33,660 $22,000
Q1 2019 May 14, 2019	BUY	$0.51 - $0.82 $4,574 - $7,355	8,970 Added 31.37%	37,563 $23,000
Q4 2018 Feb 13, 2019	BUY	$0.48 - $1.1 $13,724 - $31,452	28,593 New	28,593 $13,000
Q3 2018 Nov 13, 2018	SELL	$1.06 - $1.69 $43,133 - $68,769	-40,692 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$1.56 - $2.51 $21,117 - $33,977	-13,537 Reduced 24.96%	40,692 $64,000
Q1 2018 May 15, 2018	BUY	$0.91 - $2.24 $12,000 - $29,538	13,187 Added 32.13%	54,229 $116,000
Q4 2017 Feb 14, 2018	SELL	$0.78 - $2.1 $41,889 - $112,778	-53,704 Reduced 56.68%	41,042 $38,000
Q3 2017 Nov 14, 2017	BUY	$1.55 - $1.82 $102,777 - $120,680	66,308 Added 233.17%	94,746 $167,000
Q2 2017 Aug 14, 2017	BUY	N/A	28,438	28,438 $44,000

Others Institutions Holding DRRX

# of Institutions

Shares Held

593K

Call Options Held

Put Options Held

View Full List

About DURECT CORP

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $173M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

More about DRRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account